source
- Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidateCapricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…
- FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancerThe FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…